eligibility_summary
Adults ≥18, consented, advanced/metastatic solid tumors (dose escalation), ECOG ≤1, life expectancy ≥12 wks, measurable disease, adequate organ function, tumor tissue/biopsy available as required, WOCBP negative pregnancy test, stable treated CNS mets allowed. Excl: unstable CNS dz, recent major surgery, significant CV/GI/pulmonary disease, ≥G2 neuropathy, live vaccine <4 wks, active 2nd cancer, serious illness/infection, recent prior therapy, pregnant/nursing, recent therapeutic anticoagulation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: JK06, an intravenously administered biparatopic anti‑5T4 antibody‑drug conjugate (ADC). Mechanism: JK06 binds two epitopes on the 5T4 (TPBG) antigen on tumor cells to enhance binding and internalization, then delivers a linked cytotoxic payload intracellularly to kill 5T4‑expressing cells. Drug type: targeted ADC (immunotherapy/targeted chemotherapy). Targets: 5T4‑positive solid tumor cells, 5T4 is an oncofetal surface glycoprotein highly expressed across many solid tumors with limited normal tissue expression and is associated with tumor cell motility and invasion. Trial: first‑in‑human Phase 1/2 dose escalation (3+3) and expansion to determine MTD/RP2D, safety, PK/PD, immunogenicity, and preliminary efficacy on a 21‑day cycle in unresectable/metastatic solid tumors.